메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

Aurzen Brings Pocket-Sized Projection and Immersive Audio to MWC 2026

BARCELONA, Spain, March 2, 2026 -- Aurzen is presenting its portable entertainment lineup at Mobile World Congress 2026 in Barcelona, featuring the ZIP series and BOOM audio projectors. Built for flexible, on-the-go use, the products combine portability, ease, and performance. ZIP Series: Pocket-Sized Projection, Anywhere You Want ItThe ZIP Cyber Edition and standard ZIP models fold into a pocket-ready design while projecting at any angle, including ceilings. No wires or WiFi are needed—just unfold and watch at home, outdoors, or on the move. Accessories expand versatili
- 김장윤(JASON KIM) 기자
- 2026-03-02 13:00
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year

SHANGHAI, March 2, 2026 -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been included in the S&P Global Sustainability Yearbook 2026 ("Yearbook") in recognition of its strong performance in the 2025 Corporate Sustainability Assessment (CSA). The company was ranked top in its industry and achieved a Top 1% S&P Global CSA Score, marking the fourth consecutive year that WuXi Biologics has received this highest level of distinction. The Yearbook aims to highlight individual compa
- 김갑성 기자
- 2026-03-02 11:21
AWM Spring Dinner 2026 Gathers Over 70 Insurers to Mark a Year of Corporate Solutions

HONG KONG, March 2, 2026 -- AutoMate Wealth Management Limited (AWM), a leading insurance brokerage firm in Hong Kong, successfully hosted its annual AWM Spring Dinner 2026 on February 27, 2026, at Cloud 39, located in The Henderson — one of Hong Kong's premier international landmarks. The event brought together representatives from over 70 leading international and major local insurance companies, along with business partners, to celebrate shared success and strengthen collaboration. AWM has earned market trust through a professional, innovative, and client–centric approach, o
- 김갑성 기자
- 2026-03-02 10:54
Nopporn Suppipat divests all interest in Wind Energy Holding to Harbour

BANGKOK, March 2, 2026 -- Harbour, a UK-based investor, has assumed Nopporn "Nick" Suppipat's rights and title to all interests that he and his affiliated companies have in Wind Energy Holding Co. Ltd ("WEH"). This includes Nick's beneficial interest in Golden Music Limited ("GML"), a Hong Kong incorporated company which is the registered holder of 38% of the issued shares of WEH and is under independent, court appointed receivership. As Thailand's leading domestic wind energy company, WEH is expected to play a pivotal role in helping the
- 황정호 기자
- 2026-03-02 10:00
Synpulse Builds On 30‑Year Anniversary Momentum with APAC Leaders Andreas Mettenberger and Adrien Thonet Elevated to Partner

SINGAPORE, March 2, 2026 -- Synpulse, the global consultancy to major financial institutions, is proud to announce the promotion of Andreas Mettenberger and Adrien Thonet to Partner. Their appointments come at a defining moment for Synpulse, as the firm marks its 30‑year anniversary and reflects a journey shaped by global expansion, technological innovation, and a deepening leadership footprint across the Asia‑Pacific region. Built on deep industry expertise and a strong commitment to delivering meaningful client impact, Synpulse's 30-year journey has charted an a
- 황정호 기자
- 2026-03-02 10:00
갤럭시코퍼레이션, 스타 플러스 레전드 홀딩스와의 파트너십을 통해 글로벌 IP 전략 강화

[ 메디채널 황정호 기자 ] 서울, 한국 2026년 3월 1일 -- 한국의 지속적인 혁신 주도형 경제 성장과 함께 2025년 리벨리온(Rebellion), 퓨리오사AI(Furiosa AI), 비나우(Vinau), 그리고 갤럭시코퍼레이션(Galaxy Corporation)이 기업가치 1조 원을 돌파한 유니콘 기업으로 인정받으면서 자본시장의 뜨거운 관심을 받았다. 이 중 엔터테인먼트 테크 기업인 갤럭시코퍼레이션은 최정상급 아티스트 자원과 첨단 기술 역량을 바탕으로 기술, 엔터테인먼트, 콘텐츠 생태계를 결합한 통합 개발 모델을 통해 글로벌 영향력을 지속적으로 확대해 왔다. 2026년 1월 이재명 대통령의 중국 국빈 방문 기간 중, 경제사절단 내 최연소 최고경영자(CEO)로 동행한 갤럭시코퍼레이션의 최용호(Choi Yong-ho) 최고경영자 겸 최고행복책임자(Chief Happiness Officer)는 차이나 데일리(China Daily)를 비롯한 중국 주요 언론과 인터뷰를 진행했다. 최용호 CEO는 중국 시장이 '사실상 무한한 발전 잠재력'을 지니고 있다며, 다양한 산업 전반에 걸친 창의성, 혁신 역량, 활력을 높이 평가했다. 최
- 황정호 기자
- 2026-03-02 09:31
Everyware Limited Launches Caterlord Checkout to Redefine Self-Service Payments for Restaurants in Hong Kong

HONG KONG, March 2, 2026 -- Everyware Limited today announced the launch of Caterlord Checkout, a new self-service payment solution designed to help Hong Kong restaurants speed up bill settlement, reduce labour pressure, and deliver a smoother guest experience. Fully integrated with the Caterlord POS platform, Caterlord Checkout enables restaurants to turn tables faster while maintaining accurate, secure, and fully digital payment workflows. A new era of self‑payment Caterlord Checkout is a dedicated self-checkout kiosk that allows guests to review their bill and pay ind
- 황정호 기자
- 2026-03-02 09:00
XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication

- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with multiple myeloma (MM). - In South Korea, XPOVIO® has been approved for three indications across MM and diffuse large B-cell lymphoma (DLBCL), and two of these approved indications have been included in the national reimbursement scheme. SHANGHAI and HONG KONG, March 2, 2026 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech c
- 김갑성 기자
- 2026-03-02 08:30
Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis

[ 메디채널 김갑성 기자 ] SHANGHAI, HANGZHOU, China and BOSTON, March 2, 2026 -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced positive topline results from its Phase III clinical trial evaluating zemprocitinib in patients with moderate-to-severe atopic dermatitis (AD). The study met all co-primary and key secondary endpoints, with both dose groups demonstrating highly and statistically significant improvements versus placebo (p < 0.0001), together wi
- 김갑성 기자
- 2026-03-02 08:00
Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

SAN FRANCISCO and SUZHOU, China, March 2, 2026 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces the non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, Jaypirca® (pirtobrutinib), has received approval by the National Medical Products Administration (NMPA) in China for a new indication for the treatment of adult patients wit
- 김갑성 기자
- 2026-03-02 08:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 02일 18시 40분